Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Cited In for PubMed (Select 18442879)

1.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V.

Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. Review.

2.

IVIVC from Long Acting Olanzapine Microspheres.

D'Souza S, Faraj JA, Giovagnoli S, Deluca PP.

Int J Biomater. 2014;2014:407065. doi: 10.1155/2014/407065. Epub 2014 Jan 22.

3.

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L.

BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.

4.

Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Smeraldi E, Cavallaro R, Folnegović-Šmalc V, Bidzan L, Emin Ceylan M, Schreiner A.

Ther Adv Psychopharmacol. 2013 Aug;3(4):191-9. doi: 10.1177/2045125313479127.

5.

Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jäger M.

Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99. doi: 10.1177/2045125312464106.

6.

Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Olivares JM, Sermon J, Hemels M, Schreiner A.

Ann Gen Psychiatry. 2013 Oct 23;12(1):32. doi: 10.1186/1744-859X-12-32.

7.

Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.

Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L.

Ther Adv Psychopharmacol. 2011 Aug;1(4):111-24. doi: 10.1177/2045125311413006. Erratum in: Ther Adv Psychopharmacol. 2011 Oct;1(5):163.

8.

Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Jeong HG, Lee MS.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):1-6. doi: 10.9758/cpn.2013.11.1.1. Epub 2013 Apr 24.

9.

Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Miller BJ, Bodenheimer C, Crittenden K.

Clin Psychopharmacol Neurosci. 2011 Aug;9(2):45-53. doi: 10.9758/cpn.2011.9.2.45. Epub 2011 Aug 31.

10.

Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Kim B, Lee SH, Yang YK, Park JI, Chung YC.

Schizophr Res Treatment. 2012;2012:560836. doi: 10.1155/2012/560836. Epub 2012 Aug 14.

11.
12.

Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Viala A, Cornic F, Vacheron MN.

Schizophr Res Treatment. 2012;2012:368687. doi: 10.1155/2012/368687. Epub 2012 Apr 3.

13.

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L.

Neuropsychiatr Dis Treat. 2012;8:375-85. doi: 10.2147/NDT.S32581. Epub 2012 Aug 27.

14.
15.

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results.

Macfadden W, DeSouza C, Crivera C, Kozma CM, Dirani RD, Mao L, Rodriguez SC.

BMC Psychiatry. 2011 Oct 14;11:167. doi: 10.1186/1471-244X-11-167.

16.

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E.

Neuropsychopharmacology. 2010 Nov;35(12):2367-77. doi: 10.1038/npp.2010.111. Epub 2010 Aug 4. Erratum in: Neuropsychopharmacology. 2011 Jan;36(2):548.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk